FOCUS-Amgen's new migraine drug hits insurance hurdles

July 26, 2018 at 01:00 AM EDT

Amgen Inc's push to get patients on its new $575 a month migraine drug before competition emerges in September is facing barriers from insurers.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.